Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.
Duranti, S., Fabi, A., Filetti, M., Falcone, R., Lombardi, P., Daniele, G., Franceschini, G., Carbognin, L., Palazzo, A., Garganese, G., Paris, I., Scambia, G., Pietragalla, A., Breast cancer drug approvals issued by EMA: A review of clinical trials, <<CANCERS>>, 2021; 13 (20): 1-17. [doi:10.3390/cancers13205198] [http://hdl.handle.net/10807/190386]
Breast cancer drug approvals issued by EMA: A review of clinical trials
Daniele, Gennaro;Franceschini, Gianluca;Palazzo, Antonella;Garganese, Giorgia;Paris, Ida;Scambia, Giovanni;
2021
Abstract
Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Breast Cancer Drug Approvals Issued by EMA A Review of Clinical Trials.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
817.73 kB
Formato
Adobe PDF
|
817.73 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
